Giaconda: Myoconda study shows some of highest efficacy ever in treatment of Crohn's

By E. Janene Geiss

Philadelphia, Jan. 18 - Giaconda Ltd. said Wednesday that further clinical analysis of 53 patients treated with the Myoconda combination for a minimum of six months demonstrates some of the highest efficacy levels ever shown in the treatment of Crohn's Disease.

According to the retrospective analysis, which was presented at a recent gastroenterology medical conference in Australia, 65% of patients showed complete remission and more than 95% showed marked improvement. One patient has been in remission for nine and a half years, officials said in a company news release.

"We are excited about these results. It is one more significant study showing that treatment of Mycobacterium avium ss paratuberculosis infection in Crohn's Disease can help patients get better. There has been no effective treatment for a large number of Crohn's patients that has shown similar response rates," Tom Borody, chief medical officer, said in the release.

Myoconda is in clinical and manufacturing development and has completed a large phase 3a clinical trial in Australia. A second phase 3 study is in the planning stages, officials said.

Giaconda is a Sydney, Australia biotechnology company involved in developing and licensing new and cost-effective medical therapies in the field of gastroenterology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.